Reuters logo
AstraZeneca drug sales fall on patent expiries in second quarter
August 1, 2013 / 6:21 AM / 4 years ago

AstraZeneca drug sales fall on patent expiries in second quarter

LONDON, Aug 1 (Reuters) - AstraZeneca sales fell by a slightly more -than-expected 6 percent in the second quarter, hurt by loss of patent protection on key drugs, while earnings tumbled nearly a quarter due to a higher tax rate.

New Chief Executive Pascal Soriot is striving to turn around the business after a series of setbacks in research and a wave of patent expiries, but has warned that fixing Britain’s second biggest drugmaker will take several years.

The group reiterated its expectation for a mid-to-high single digit percentage fall in revenue this year, while operating costs are now seen increasing by a low-to-mid single digit rate. Earnings are expected to decline significantly more than revenue in 2013.

Sales in the quarter were $6.232 billion, generating “core” earnings, which exclude certain items, down 23 percent at $1.20 a share, AstraZeneca said on Thursday.

Analysts had, on average, forecast sales of $6.248 billion and earnings of $1.20, according to Thomson Reuters I/B/E/S.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below